using tissu microarray tmas studi cox2 pparg immunoreact broad spectrum tumor focuss clinicopatholog correl outcom patient malign melanoma tma1 contain normal tumor tissu from 47 organ includ skin neoplasm tma2 88 primari 101 metastas 161 benign nevi base biomodulatori approach combin cox ppartarget metronom lowdos chemotherapi metastas 36 patient particip random trial metastat stage melanoma were investig use tma3 cox2 pparg immunoreact signific increas from nevi primari metastas cox2 posit associ advanc clark level shorter recurrencefre surviv patient ppargposit metastas biomodulatori metronom chemotherapi alon combin cox2 ppargtarget show signific prolong progressionfre surviv regard primari cox2 express indic increas risk tumor recurr metastat pparg express may predicit marker respons biomodulatori stromatarget therapi

Stefanie Meyer

Thomas Vogt

Michael Landthaler

Anna Berand

Albrecht Reichle

Frauke Bataille

Andreas H. Marx

Anne Menz

Arndt Hartmann

Leoni A. Kunz-Schughart

Peter J. Wild

Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma

About this journal

PPAR Research publishes articles related to mechanisms involved in the activation of peroxisome proliferator-activated receptors, as well as their role in regulation of cellular differentiation, development, energy homeostasis and metabolic function.

Journal profile

Meet the editorial board

PPAR Research maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.

PPAR Research

Table of Contents

Table of Contents: 2010

Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma